Tempus AI, Inc. (TEM)
| Market Cap | 12.33B |
| Revenue (ttm) | 1.11B |
| Net Income (ttm) | -203.88M |
| Shares Out | 177.91M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,234,783 |
| Open | 66.84 |
| Previous Close | 67.15 |
| Day's Range | 66.15 - 69.34 |
| 52-Week Range | 31.66 - 104.32 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 80.42 (+16.08%) |
| Earnings Date | Feb 23, 2026 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]
Financial Performance
In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $80.42, which is an increase of 16.08% from the latest price.
News
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation's premier academic medical centers, today announced a multi-year...
Here's why the Tempus AI stock may surge 47% soon
Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. It has slumped to $66, with its market capitalization slumping from $17.8 billion in Octob...
Northwestern Medicine Selects Tempus to Expand Genomic Testing
CHICAGO--(BUSINESS WIRE)--Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provid...
Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve—Vistra, Tempus AI, Alibaba In Focus
U.S. stock futures declined on Monday after a positive close on Friday. Futures of major benchmark indices were trading lower.
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 bil...
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the f...
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for pres...
Rune Labs Taps Tempus Exec as New CEO to Expand AI-Enabled Neurology Care
SAN FRANCISCO--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for neurology, today announced Amy Gordon Franzen as its new Chief Executive Officer. Amy will lead the company's next stage...
Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Confe...
Tempus AI: A Healthcare Hyper-Growth Opportunity For The Risk Tolerant
Tempus AI (NASDAQ:TEM) is rated a strong buy for risk-tolerant investors, leveraging its vast proprietary healthcare data to drive precision medicine via AI and ML. TEM delivered 85% YoY revenue growt...
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Tempus AI: Plenty Of Growth Catalysts Ahead, Grab It While It's Down
Tempus AI remains a Buy after a market-driven correction, with operational performance and partnerships strengthening the long-term thesis. TEM's organic revenue grew 28% y/y, gross margins improved 4...
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presen...
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcar...
Tempus AI: Opportunity To Build Position
Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry acquisitio...
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and bei...
Tempus AI, Inc. (TEM) Presents at Stifel 2025 Healthcare Conference Transcript
Tempus AI, Inc. ( TEM) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel,...
Tempus AI: Great Buying Opportunity On Recent Weakness
Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid p...
Tempus AI: A Good Bet For The Future Of Health Care
Tempus AI remains a buy as its data set, testing volumes, and financial results continue to show robust growth. TEM's Genomics segment drives strong revenue growth, with oncology and hereditary testin...
Tempus AI: First Positive EBITDA, Huge TAM - Yet The Stock Isn't A Buy
Tempus AI is building a strong moat in healthcare AI with vast clinical/genomic datasets and robust infrastructure, driving high-growth potential. TEM achieved its first positive adjusted EBITDA in Q3...
Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says
BTIG analyst Mark Massaro reiterated a Buy rating for Tempus AI, Inc. (NASDAQ:TEM) with a price target of $96 following the third-quarter FY25 earnings beat.
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presen...
Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript
Tempus AI, Inc. ( TEM) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric Lefkofsky - ...